Barnebey, H.S., Orengo-Nania, S., Flowers, B.E., et al. (2005) The Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Fixed Combination Ophthalmic Solution. American Journal of Ophthalmology, 140, 1.e1-1.e8.
https://doi.org/10.1016/j.ajo.2005.02.043

has been cited by the following article:

• TITLE: Efficacy and Safety of Travoprost and Timolol Fixed Combination Compared to Travoprost in Patients with Primary Open Angle Glaucoma and Ocular Hypertension

  AUTHORS: Gentian Hoxha, Kelmend Spahiu, Gazmend Kaçaniku, Mimoza Ismaili, Fëllanza Ismajli-Hoxha

  KEYWORDS: Open Angle Glaucoma, Ocular Hypertension, Travoprost/Timolol Fixed Combination, Adverse Event

  JOURNAL NAME: Open Journal of Ophthalmology, Vol.7 No.3, July 17, 2017

  ABSTRACT: Purpose: To compare intraocular pressure (IOP)-lowering efficacy and safety of travoprost 0.004% and travoprost 0.004% and beta-blocker 0.5% fixed combination ophthalmic solution in patients with open-angle glaucoma and ocular hypertension. Methods: In this prospective, multicentre clinical trial, 62 patients received travoprost 0.004% (n = 31) or travoprost 0.004% and beta-blocker 0.5% fixed combination (n = 31). Efficacy and safety were compared across treatment groups over 2 years. IOP reduction and adverse events were examined at 3, 6, 12 and 24 months for each group. Results: Mean IOP at the first visit in the travoprost 0.004% group was 26.4 (SD ± 2.1), and travoprost 0.004%/timolol 0.5% group was 26.3 (SD ± 2.1). Mean IOP after 24 months in the travoprost 0.004% group was 20.5 (SD ± 1.5) and travoprost 0.004%/timolol 0.5% group was 18.5 (SD ± 1.5). There were statistically significant differences in IOP in both eyes after third visit (after 1 year) and fourth visit (after 2 years). Conclusion: After 2 year of treatment, travoprost 0.004%/timolol 0.5% produced clinically relevant IOP reductions in patients with open-angle glaucoma or ocular hypertension that were greater than those produced by travoprost 0.004% alone.